DMAC vs SLB · $157.4M cap vs P/E 12, rev $35.71B
DiaMedica Therapeutics Inc (DMAC) versus Schlumberger NV (SLB) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Schlumberger NV (SLB) is a oil & gas equipment & services company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported SLB revenue for 2025-12-31 was $35.71B. Net income was $3.37B. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
DMAC currently screens at market cap $157.4M. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
Not investment advice. Open the DMAC and SLB stock pages for the full models.
Not investment advice.